Please ensure Javascript is enabled for purposes of website accessibility

Weekly Cannabis Stock News: Aphria, HEXO, and Cresco Labs Find Fresh Capital

By Eric Volkman - Jan 26, 2020 at 3:28PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Capital raising, executive and board member comings and goings... it sure was a busy five days.

For the marijuana industry, last week was fairly eventful. The individual happenings weren't necessarily momentous, but they matter in a business that in many ways is still finding its way to success.

We can break them down into two categories -- fund raising and executive shifts -- and there were several instances of both.

Marijuana leaf atop a $100 bill.

Image source: Motley Fool

It's time for some cannabis capital raising

Three cannabis businesses, three different new sources of funding.

Last week Aphria (APHA), HEXO (HEXO 3.11%), and Cresco Labs (CRLBF -0.89%) all announced they had secured fresh capital. Aphria and HEXO did it through the sale of stock, while Cresco Labs signed on the dotted line for credit.

The equity guys also differed in how said stock was handed out. Aphria is accepting a 100 million Canadian dollar ($76 million) cash infusion from an institutional investor that, for some reason, wasn't revealed. In exchange, Anonymous New Stockholder is receiving slightly more than 14 million Aphria "units", each of which contains one share of common stock and one warrant to buy half of a share in the future.

HEXO closed a direct stock offering, in the latest in a series of share sales. This one brought in gross proceeds of $20 million. Like Aphria, HEXO packaged shares and warrants together. The score for HEXO was nearly 12 million shares, and warrants carrying the right to buy almost 6 million more.

Finally, Cresco Labs went the borrowing route. It obtained a senior secured term loan credit facility for up to $200 million; as much as $100 million will be drawn down by the company at the end of this month. Each of the draws on this credit, provided by a syndicate of lenders which were not individually identified, will have a term of 18 or 24 months. Interest rates start at roughly 12.7%.

Although it's good news for all three that they're getting some new, badly needed capital, there are significant downsides, too. The share counts of both Aphria and HEXO have ballooned over the years. Dilution often spooks would-be investors from buying a company's stock, and discourages current shareholders. Cresco's new credit, meanwhile, bears interest rates that -- while not unusual for pot companies -- are onerous nevertheless.

HEXO Shares Outstanding Chart

HEXO Shares Outstanding data by YCharts

Executive decisions

The week after Tilray brought in a new CFO and COO saw high-level personnel moves in two of the cannabis company's peers.

On the arrivals side of the platform we have Canopy Growth (CGC 2.79%), which named its next board chair and brought on a new director. In line with other recent human resources changes at the company, these two people are connected with Canopy Growth's leading investor, alcoholic drinks specialist Constellation Brands (STZ 0.61%).

The new chair is existing board member Judy Schmeling, while the new arrival is Constellation marketing executive Jim Sabia. Schmeling, by the way, takes over as chair from David Klein, the recently installed CEO of Canopy Growth. No prizes for guessing what company Klein formerly worked for -- that's right, Constellation, where he was CFO. So it looks very much like the booze specialist continues to tighten its grip on the company.

Switching to the departures end of the building, Cronos Group (CRON 3.21%) divulged in a regulatory filing the resignations of both chief operating officer David Hsu and chief commercial officer William Hilson. This was uncomfortable news to begin with, compounded by the fact that these exits had officially taken place weeks before Cronos got around to announcing them (both resignations were effective Dec. 31, 2019).

The Constellation-ization of Canopy Growth can be beneficial, as the so-called Cannabis 2.0 market in Canada is currently underway (although the company isn't quite as ready for it as many had hoped). The big shareholder can bring much expertise and help to the weed-infused drinks segment of that market.

The developments at Cronos are more troubling, since not one but two top executives are departing, and the cannabis company wasn't immediately forthright about this development. Cronos hasn't, by the way, publicly named replacements yet.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Canopy Growth Stock Quote
Canopy Growth
$5.89 (2.79%) $0.16
Cronos Group Stock Quote
Cronos Group
$3.54 (3.21%) $0.11
HEXO Stock Quote
$0.33 (3.11%) $0.01
Aphria Stock Quote
Cresco Labs Inc. Stock Quote
Cresco Labs Inc.
$3.90 (-0.89%) $0.04
Constellation Brands, Inc. Stock Quote
Constellation Brands, Inc.
$250.95 (0.61%) $1.53
Tilray Stock Quote

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.